TRML Tourmaline Corp: Earnings per share for the last twelve months
Tourmaline Bio, Inc. (TRML) focuses on developing innovative antibodies to combat severe inflammation. The 12-month net income per share history demonstrates that the current parameter is -3.41. Simultaneously, the company is implementing "green" standards in its laboratories to reduce toxic waste. Share price growth is expected following the completion of phase II trials for its ophthalmology drug, despite the current lack of revenue.
Analytical breakdowns and data insights for company Tourmaline Bio Inc (TRML)
- current quotes and average value forecast:
- company stock capitalization data:
- shareholders' equity book value data:
- debt and liquidity data:
Total Debt to Capital Tourmaline Bio, Inc.|TRML - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Tourmaline Corp|TRML - Company Cumulative Indebtedness|Debt to Book Capitalization Ratio Tourmaline Bio, Inc.|TRML - Long-Term Debt|Company Current Liabilities Tourmaline Bio|Quick Liquidity tourmalinebio.com
- earnings and valuation multiples indicators:
TRML - Final Profit|Expected Profit Tourmaline Bio, Inc.|TRML - Price to Earnings Ratio|Forward P/E Multiple Tourmaline Bio|TRML - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tourmaline Bio, Inc.|TRML - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Tourmaline Bio|TRML - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months tourmalinebio.com|TRML - Earnings per share growth this year|Earnings growth forecast for next year Tourmaline Bio, Inc.
Summary company analytics:TRML - Tourmaline Bio, Inc.
The stability of Tourmaline Bio, Inc. (TRML) depends on the successful development of the tourmaline-001 antibody to capture the thyroid eye disease treatment niche. This metric aggregates net income over the last 12 months, allocating it per share to assess the actual profitability of the business without accounting for capital dilution. Analyzing the TTM earnings per share chart allows an investor to promptly identify growth stagnation and minimize the risks of deep drawdowns.
Main competitors
ARGX - Earnings per share for the last twelve months|biontech.de (BNTX) - Net earnings per share for the last 12 months|Abivax Pharma (ABVX) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months ADMA Biologics Inc|Net earnings per share for the last 12 months PTGX|Net earnings per share (EPS TTM) Immunovant Therapeutics|Earnings per share for the last twelve months Kiniksa Pharmaceuticals (KNSA)|grifols.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) ADPT (Adaptive Biotechnologies Corporation)|Celldex Therapeutics Inc (CLDX) - Net earnings per one share for the last twelve months|AUPH: Net earnings per share for the last 12 months|BioCryst Corp - Earnings per share for the last four quarters|Vera Therapeutics, Inc. (VERA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months dianthustx.com (DNTH)|Net earnings per share for the last 12 months PHVS|Net earnings per share (EPS TTM) AbCellera Biologics Inc|Earnings per share for the last twelve months Intrexon (PGEN)|PHAR (Pharming Corp) - Earnings per share for the trailing year|Earnings per share for the last twelve months Nektar Therapeutics NKTR|UPB - Net earnings per share for the last 12 months|Zenas Biopharma - Net earnings per share (EPS TTM)|IMNM - Net earnings per share (EPS TTM)|Gossamer Corp (GOSS) - Earnings per share for the last twelve months|KALV (KalVista Corp) - Earnings per share for the last twelve months|SEPN (Septerna Inc) - Net earnings per share (EPS TTM)|pieris.com (PVLA) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Savara (SVRA)|Rigel Pharma - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) ANAB (AnaptysBio Corp)|Astria Corp (ATXS) - Net earnings per one share for the last twelve months|ENGN: Net earnings per share for the last 12 months|Earnings per share for the trailing year RAPT (RAPT Therapeutics Inc.)|JBIO: Net earnings per share (EPS TTM)|ACRS (Aclaris Therapeutics Inc.) - Earnings per share for the last twelve months|KYTX (Kyverna) - Net earnings per share (EPS TTM)|Tiziana Life Sciences, Ltd. (TLSA) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Cabaletta Bio, Inc. (CABA)|VTYX - Net earnings per one share for the last twelve months|Theratechnologies - Net earnings per share for the last 12 months|Earnings per share for the trailing year AVTX|Eledon - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Agenus, Inc AGEN|Climb Bio Inc (CLYM) - Earnings per share for the last twelve months|Earnings per share for the last 12 months ZURA|ATYR (aTyr Pharma) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Adagene Corp (ADAG)|Net earnings per share for the last 12 months IMA (ImageneBio Inc)|Net earnings per share for the last four quarters shattucklabs.com|Equillium - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CNTB (Connect Biopharma Holdings)|IMUX - Earnings per share for the last twelve months|Earnings per share for the trailing year ATRA (Atara Biotherapeutics)|inflarx.de (IFRX) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months X4 Pharmaceuticals, Inc|Earnings per share for the last twelve months Adicet Bio Inc.|Earnings per share for the last twelve months CELU|Earnings per share for the last twelve months INmune Bio (INMB)|BRNS: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) KZR (Kezar Life Sciences, Inc)|Earnings per share for the trailing year SABS|Akari Therapeutics - Net earnings per share (EPS TTM)|ENLV - Net earnings per share (EPS TTM)|q32bio.com (QTTB) - Earnings per share for the last twelve months|GeoVax Labs - Earnings per share for the trailing year|Earnings per share for the last twelve months Edesa|Net earnings per share for the last 12 months iBio Corporation (IBIO)|Net earnings per share (EPS TTM) CARM|Net earnings per share (EPS TTM) xtlbio.com (XTLB)|Bolt Biotherapeutics, Inc. - Net earnings per share for the last 12 months|Earnings per share for the trailing year HCWB|Aptevo - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters AIM ImmunoTech, Inc. AIM|aditxt.com (ADTX) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months gribio.com|Earnings per share for the last twelve months XORTX Therapeutics|Net earnings per share for the last 12 months Vyome Holdings Inc. (HIND)|Net earnings per share for the last 12 months REVB (Revelation Bio)|Net earnings per share (EPS TTM) Indaptus Corp (INDP)|Earnings per share for the last twelve months Scinai Immunotherapeutics SCNI|CALI: Earnings per share for the last 12 months|Affimed Therapeutics - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Allakos Inc.|HOOK (hookipapharma.com) - Net earnings per share for the last 12 months|IGMS: Earnings per share for the last four quarters|Earnings per share for the last twelve months iTeos Therapeutics|Net earnings per one share for the last twelve months oceanbiomedical.com OCEA|Net earnings per share for the last 12 months TCBP (TC BioPharm)|Net earnings per share (EPS TTM) Third Harmonic Bio Inc. (THRD)
